Work

Phase Ia, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic, or biliary cancers.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.4_suppl.713

Authors: Andrew H. Ko, Andrew L. Coveler, Benjamin L. Schlechter, Tanios S. Bekaii-Saab, Brian M. Wolpin, Jeffrey William Clark, Yi-Lin Cheng, Ting-Ying Cheng, Peter J. Langecker, Shih-Yao Lin

Institutions: UCSF Helen Diller Family Comprehensive Cancer Center, Seattle Cancer Care Alliance, University of Washington, Beth Israel Deaconess Medical Center, Mayo Clinic Hospital, Dana-Farber Cancer Institute, Massachusetts General Hospital, zyBooks, Sistemas Genómicos, Catalent (United States), SATO Pharmaceutical Co., Ltd. (Japan)

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4243871152

Cites:

Cited by: 3

Related to: 10